Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bearish -20

Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?

Company update AI-generated analysis

πŸ“ˆ Moderna (MRNA) rejoined the Nasdaq-100 index after a 571% stock price recovery from a $22.28 low to approximately $196 per share.

πŸ”„ The company replaced Warner Bros. Discovery in the index, which is selected based on market capitalization rather than profitability.

πŸ’Έ Gross margins remain negative at -66.02%, meaning product costs exceed sales revenue before other expenses are considered.

πŸ“‰ Operating and net margins are severely negative at -557.93% and -141.43% respectively, reflecting ongoing operational losses.

πŸ’° Free cash flow was -$1.24 billion in the most recent quarter, indicating a continued high burn rate from core operations.

🏦 The balance sheet supports operations with $5.14 billion in cash against $1.29 billion in debt, funding roughly four years of runway.

πŸ“Š Revenue growth has stalled with only a 2.10% increase in the latest quarter, showing limited top-line momentum.

πŸ§ͺ Future sustainability depends on the drug pipeline as current products do not cover their cost of goods sold.

πŸ“‰ Return on equity is negative at -39.00%, driven by an $8.36 per share loss against a book value of $16.95.

πŸ“‰ Forward earnings multiples are negative due to expected losses in the coming year, despite a trailing P/E of 35.21x.

πŸ“‰ Hedge fund ownership decreased slightly to 49 funds with a combined stake of $1.54 billion as of Q2 2026.

πŸ“‰ Short interest stands at 10.06% of the float, indicating significant bearish positioning among some investors.

Bullish Signals
  • Moderna's market capitalization recovered to $78.44 billion, triggering its re-entry into the Nasdaq-100 index.
  • The company holds a robust balance sheet with $5.14 billion in cash against only $1.29 billion in debt.
Risk Factors
  • Gross margins are negative at -66.02%, indicating that the cost of producing products exceeds revenue.
  • Operating margin is severely negative at -557.93%, reflecting significant operational inefficiencies or losses.
  • Net margin remains deeply negative at -141.43%, showing a substantial loss relative to total revenue.
  • Free cash flow was -$1.24 billion in the most recent quarter, highlighting a high burn rate.
Full Analysis
Moderna (MRNA) has been reinstated to the Nasdaq-100 index, replacing Warner Bros. Discovery, following a significant recovery in its market capitalization. The company's stock price surged approximately 571% over the last twelve months, rising from a low of $22.28 to around $196 per share as of October 7, 2026. This valuation increase pushed Moderna's market cap to roughly $78.44 billion, clearing the threshold required for index membership after its removal in December 2024. However, this index re-entry is driven strictly by market value metrics rather than an improvement in underlying business fundamentals. Despite the stock rally, Moderna continues to report negative gross margins of -66.02%, indicating that the cost of producing its products exceeds revenue. Additionally, operating and net margins remain deeply negative at -557.93% and -141.43% respectively, with free cash flow standing at -$1.24 billion for the most recent quarter. The company's financial sustainability currently relies on its balance sheet rather than earnings power, holding $5.14 billion in cash against $1.29 billion in debt, which provides roughly four years of runway at current burn rates. Revenue growth has stagnated with only a 2.10% increase in the latest quarter, and analysts note that Moderna's future viability depends entirely on its pipeline rather than current products which fail to cover costs. The article concludes that while the stock price has recovered, the income statement has not. Institutional interest remains mixed, with hedge fund holdings slightly decreasing from 52 to 49 funds in Q2 2026, reducing their cumulative stake value from $1.40 billion to $1.54 billion. Short interest stands at 10.06% of the float, suggesting a portion of investors remain skeptical about the recovery despite the index inclusion. The article emphasizes that the Nasdaq-100 selection criteria do not evaluate profitability or cash flow, allowing Moderna's return based solely on its market cap rebound.